$OVID
Ovid Therapeutics Inc.

2022 Q1 Form 10-Q Financial Statement

#000095017022008739 Filed on May 10, 2022

View on sec.gov

Income Statement

Concept 2022 Q1 2021 Q1
Revenue $1.445M $208.4M
YoY Change -99.31%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $9.900M $15.60M
YoY Change -36.54% 173.68%
% of Gross Profit
Research & Development $7.832M $16.25M
YoY Change -51.8% 11.1%
% of Gross Profit
Depreciation & Amortization $73.81K $74.74K
YoY Change -1.24% 11.75%
% of Gross Profit
Operating Expenses $17.71M $31.83M
YoY Change -44.34% 56.82%
Operating Profit -$16.27M $176.6M
YoY Change -109.21% -969.98%
Interest Expense $200.0K $0.00
YoY Change -100.0%
% of Operating Profit 0.0%
Other Income/Expense, Net $209.1K
YoY Change
Pretax Income -$16.06M $176.5M
YoY Change -109.1% -981.21%
Income Tax $50.00K $500.3K
% Of Pretax Income 0.28%
Net Earnings -$16.11M $176.0M
YoY Change -109.15% -978.71%
Net Earnings / Revenue -1114.46% 84.46%
Basic Earnings Per Share -$0.23 $2.55
Diluted Earnings Per Share -$0.23 $2.53
COMMON SHARES
Basic Shares Outstanding 70.35M 66.09M
Diluted Shares Outstanding 70.35M 66.58M

Balance Sheet

Concept 2022 Q1 2021 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $166.7M $233.1M
YoY Change -28.49% 299.6%
Cash & Equivalents $166.7M $233.1M
Short-Term Investments
Other Short-Term Assets $2.400M $2.600M
YoY Change -7.69% 30.0%
Inventory
Prepaid Expenses
Receivables $1.000M
Other Receivables $0.00
Total Short-Term Assets $170.1M $236.7M
YoY Change -28.14% 289.71%
LONG-TERM ASSETS
Property, Plant & Equipment $257.9K $100.0K
YoY Change 157.85% -8.29%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $1.600M
YoY Change
Other Assets $244.0K $400.0K
YoY Change -38.99% -8.32%
Total Long-Term Assets $21.01M $800.0K
YoY Change 2526.11% -18.84%
TOTAL ASSETS
Total Short-Term Assets $170.1M $236.7M
Total Long-Term Assets $21.01M $800.0K
Total Assets $191.1M $237.5M
YoY Change -19.54% 284.78%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.257M $3.100M
YoY Change -27.2% -22.35%
Accrued Expenses $7.971M $13.20M
YoY Change -39.61% 120.41%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $10.20M $16.30M
YoY Change -37.42% 63.13%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $15.90M $0.00
YoY Change -100.0%
Total Long-Term Liabilities $15.90M $0.00
YoY Change -100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $10.20M $16.30M
Total Long-Term Liabilities $15.90M $0.00
Total Liabilities $26.10M $16.35M
YoY Change 59.67% 59.03%
SHAREHOLDERS EQUITY
Retained Earnings -$187.5M -$118.2M
YoY Change 58.62% -49.32%
Common Stock $352.5M $339.3M
YoY Change 3.88% 19.23%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $165.0M $221.1M
YoY Change
Total Liabilities & Shareholders Equity $191.1M $237.5M
YoY Change -19.52% 284.71%

Cashflow Statement

Concept 2022 Q1 2021 Q1
OPERATING ACTIVITIES
Net Income -$16.11M $176.0M
YoY Change -109.15% -978.71%
Depreciation, Depletion And Amortization $73.81K $74.74K
YoY Change -1.24% 11.75%
Cash From Operating Activities -$20.10M $160.9M
YoY Change -112.49% -973.89%
INVESTING ACTIVITIES
Capital Expenditures $45.94K $11.51K
YoY Change 298.95% -18.57%
Acquisitions
YoY Change
Other Investing Activities -$1.000M $0.00
YoY Change -100.0%
Cash From Investing Activities -$1.076M -$11.51K
YoY Change 9246.58% -100.3%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 33.08K 129.7K
YoY Change -74.49% 734.64%
NET CHANGE
Cash From Operating Activities -20.10M 160.9M
Cash From Investing Activities -1.076M -11.51K
Cash From Financing Activities 33.08K 129.7K
Net Change In Cash -21.13M 161.0M
YoY Change -113.12% -1205.87%
FREE CASH FLOW
Cash From Operating Activities -$20.10M $160.9M
Capital Expenditures $45.94K $11.51K
Free Cash Flow -$20.15M $160.9M
YoY Change -112.52% -973.16%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
222400000
CY2022Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-187500000
CY2022Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2022Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001636651
CY2022Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2022Q1 dei Amendment Flag
AmendmentFlag
false
CY2022Q1 dei Document Type
DocumentType
10-Q
CY2022Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2022Q1 dei Document Period End Date
DocumentPeriodEndDate
2022-03-31
CY2022Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
CY2022Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2022Q1 dei Entity File Number
EntityFileNumber
001-38085
CY2022Q1 dei Entity Registrant Name
EntityRegistrantName
Ovid Therapeutics Inc.
CY2022Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2022Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
46-5270895
CY2022Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
1460 Broadway
CY2022Q1 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 15044
CY2022Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
New York
CY2022Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
NY
CY2022Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
10036
CY2022Q1 dei City Area Code
CityAreaCode
646
CY2022Q1 dei Local Phone Number
LocalPhoneNumber
661-7661
CY2022Q1 dei Security12b Title
Security12bTitle
Common Stock, par value $0.001 per share
CY2022Q1 dei Trading Symbol
TradingSymbol
OVID
CY2022Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2022Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2022Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2022Q1 dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
CY2022Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2022Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2022Q1 dei Entity Ex Transition Period
EntityExTransitionPeriod
true
CY2022Q1 dei Entity Shell Company
EntityShellCompany
false
CY2022Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
70417345
CY2022Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
166668027
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
187797532
CY2022Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2419160
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2681597
CY2022Q1 ovid Note Receivable
NoteReceivable
1000000
CY2021Q4 ovid Note Receivable
NoteReceivable
0
CY2022Q1 us-gaap Assets Current
AssetsCurrent
170087187
CY2022Q1 us-gaap Long Term Investments
LongTermInvestments
2784427
CY2021Q4 us-gaap Assets Current
AssetsCurrent
190479129
CY2021Q4 us-gaap Long Term Investments
LongTermInvestments
1631992
CY2022Q1 us-gaap Restricted Cash
RestrictedCash
1930753
CY2021Q4 us-gaap Restricted Cash
RestrictedCash
1930753
CY2022Q1 us-gaap Security Deposit
SecurityDeposit
100339
CY2021Q4 us-gaap Security Deposit
SecurityDeposit
96034
CY2022Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
257853
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
242757
CY2022Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
15691482
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
0
CY2022Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
244033
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
164092
CY2022Q1 us-gaap Assets
Assets
191096074
CY2021Q4 us-gaap Assets
Assets
194544757
CY2022Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
2256775
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
7127046
CY2022Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
7970943
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
7671275
CY2022Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
15872085
CY2021Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
0
CY2022Q1 us-gaap Liabilities
Liabilities
26099803
CY2021Q4 us-gaap Liabilities
Liabilities
14798321
CY2022Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2022Q1 us-gaap Preferred Stock Value
PreferredStockValue
1
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
1
CY2022Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
125000000
CY2022Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
125000000
CY2022Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
70417245
CY2022Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
70417245
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
70364912
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
70364912
CY2022Q1 us-gaap Common Stock Value
CommonStockValue
70373
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
70359
CY2022Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
352391466
CY2021Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
351033589
CY2022Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-187465569
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-171357513
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
164996271
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
179746436
CY2022Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
191096074
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
194544757
CY2022Q1 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
1445366
CY2021Q1 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
208382779
CY2022Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7832269
CY2021Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
16248909
CY2022Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9880203
CY2021Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
15576554
CY2022Q1 us-gaap Operating Expenses
OperatingExpenses
17712472
CY2021Q1 us-gaap Operating Expenses
OperatingExpenses
31825463
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-16267107
CY2021Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
176557316
CY2022Q1 us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
209050
CY2021Q1 us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
-49732
CY2022Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-16058056
CY2021Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
176507584
CY2022Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
50000
CY2021Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
500277
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-16108056
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
176007307
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.23
CY2021Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
2.55
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.23
CY2021Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
2.53
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
70345828
CY2021Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
66088592
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
70345828
CY2021Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
66578377
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
179746436
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1324812
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
33079
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-16108056
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
164996271
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
43631656
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1320002
CY2021Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
130173
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
20802
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
176007307
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
221109940
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-16108056
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
176007307
CY2022Q1 ovid Noncash Consideration Received In Licensing Agreement Transaction
NoncashConsiderationReceivedInLicensingAgreementTransaction
945366
CY2021Q1 ovid Noncash Consideration Received In Licensing Agreement Transaction
NoncashConsiderationReceivedInLicensingAgreementTransaction
0
CY2022Q1 us-gaap Equity Securities Fv Ni Unrealized Gain Loss
EquitySecuritiesFvNiUnrealizedGainLoss
207068
CY2021Q1 us-gaap Equity Securities Fv Ni Unrealized Gain Loss
EquitySecuritiesFvNiUnrealizedGainLoss
0
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
1324812
CY2021Q1 us-gaap Share Based Compensation
ShareBasedCompensation
1320002
CY2022Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
73807
CY2021Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
74735
CY2022Q1 ovid Accretion Of Lease Liability
AccretionOfLeaseLiability
88291
CY2022Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-262437
CY2021Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-80409
CY2022Q1 us-gaap Increase Decrease In Security Deposits
IncreaseDecreaseInSecurityDeposits
-4305
CY2021Q1 us-gaap Increase Decrease In Security Deposits
IncreaseDecreaseInSecurityDeposits
0
CY2022Q1 us-gaap Increase Decrease Due From Affiliates
IncreaseDecreaseDueFromAffiliates
0
CY2021Q1 us-gaap Increase Decrease Due From Affiliates
IncreaseDecreaseDueFromAffiliates
882028
CY2022Q1 ovid Increase Decrease In Prepaid Expense Noncurrent
IncreaseDecreaseInPrepaidExpenseNoncurrent
0
CY2021Q1 ovid Increase Decrease In Prepaid Expense Noncurrent
IncreaseDecreaseInPrepaidExpenseNoncurrent
-225116
CY2022Q1 us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
-4870271
CY2021Q1 us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
-2277334
CY2022Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
299300
CY2021Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1165847
CY2022Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
0
CY2021Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-12382779
CY2022Q1 us-gaap Increase Decrease In Due To Related Parties
IncreaseDecreaseInDueToRelatedParties
0
CY2021Q1 us-gaap Increase Decrease In Due To Related Parties
IncreaseDecreaseInDueToRelatedParties
-2432192
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-20086419
CY2021Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
160899083
CY2022Q1 ovid Payments For Proceeds From Issuance Of Short Term Note Receivable
PaymentsForProceedsFromIssuanceOfShortTermNoteReceivable
1000000
CY2021Q1 ovid Payments For Proceeds From Issuance Of Short Term Note Receivable
PaymentsForProceedsFromIssuanceOfShortTermNoteReceivable
0
CY2022Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
45935
CY2021Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
11514
CY2022Q1 us-gaap Payments To Develop Software
PaymentsToDevelopSoftware
30230
CY2021Q1 us-gaap Payments To Develop Software
PaymentsToDevelopSoftware
0
CY2022Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-1076165
CY2021Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-11514
CY2022Q1 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
0
CY2021Q1 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
21314
CY2022Q1 us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
0
CY2021Q1 us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
130173
CY2022Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
33079
CY2021Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
20802
CY2022Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
33079
CY2021Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
129661
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-21129505
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
161017230
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
189728285
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
72033930
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
168598780
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
233051160
CY2022Q1 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
15779773
CY2022Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
166700000
CY2022Q1 ovid Working Capital
WorkingCapital
159900000
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-20100000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-16100000
CY2022Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.1260416666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">(C) Use of Estimates</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.1260416666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of income and expenses during the reporting period. Actual results could differ materially from those estimates.</span></p>
CY2022Q1 ovid Restricted Cash Policy Policytextblock
RestrictedCashPolicyPolicytextblock
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">(D) Restricted Cash</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">The Company classifies as restricted cash all cash pledged as collateral to secure long-term obligations and all cash whose use is otherwise limited by contractual provisions. Amounts are reported as non-current unless restrictions are expected to be released in the next 12 months.</span></p>
CY2022Q1 us-gaap Equity Method Investments
EquityMethodInvestments
1600000
CY2021Q4 us-gaap Equity Method Investments
EquityMethodInvestments
1600000
CY2022Q1 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
166668027
CY2022Q1 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
0
CY2022Q1 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
0
CY2022Q1 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
166668027
CY2021Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
187797532
CY2021Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
0
CY2021Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
0
CY2021Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
187797532
CY2022Q1 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Number Of Positions
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions
0
CY2021Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Number Of Positions
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions
0
CY2022Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
293047
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
262208
CY2022Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
257853
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
242757
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
2316303
CY2021Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
263000
CY2022Q1 us-gaap Depreciation
Depreciation
31000
CY2021Q1 us-gaap Depreciation
Depreciation
19000
CY2022Q1 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
244000
CY2022Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
32000
CY2021Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
56000
CY2022Q1 us-gaap Lessee Operating Lease Description
LesseeOperatingLeaseDescription
During September 2021, the Company entered into a 10-year lease agreement for its corporate headquarters with a term commencing March 10, 2022, for approximately 19,143 square feet of office space at Hudson Commons in New York, NY.
CY2022Q1 us-gaap Payments For Rent
PaymentsForRent
2300000
CY2022Q1 us-gaap Lessee Operating Lease Lease Not Yet Commenced Description
LesseeOperatingLeaseLeaseNotYetCommencedDescription
Rent payments commence 10 months following the commencement date of the lease, or January 10, 2023, and continue for 10 years following the rent commencement date. Rent also includes two months of free rent in the 6th and 7th months following the rent commencement date.
CY2022Q1 us-gaap Lessee Operating Lease Remaining Lease Term
LesseeOperatingLeaseRemainingLeaseTerm
P10Y
CY2022Q1 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P5Y
CY2022Q1 ovid Lease Incremental Borrowing Rate
LeaseIncrementalBorrowingRate
0.0702
CY2022Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
15691482
CY2022Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
0
CY2022Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
15872085
CY2022Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
180603
CY2022Q1 us-gaap Variable Lease Cost
VariableLeaseCost
0
CY2022Q1 us-gaap Short Term Lease Cost
ShortTermLeaseCost
0
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
1865911
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
2316303
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
2316303
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
2316303
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
12347235
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
23478358
CY2022Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3472528
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3764666
CY2022Q1 ovid Accrued Research And Development
AccruedResearchAndDevelopment
2176030
CY2021Q4 ovid Accrued Research And Development
AccruedResearchAndDevelopment
1795190
CY2022Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1166948
CY2021Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1564955
CY2022Q1 us-gaap Settlement Liabilities Current
SettlementLiabilitiesCurrent
750000
CY2021Q4 us-gaap Settlement Liabilities Current
SettlementLiabilitiesCurrent
0
CY2022Q1 ovid Income Tax Accrual Current
IncomeTaxAccrualCurrent
266270
CY2021Q4 ovid Income Tax Accrual Current
IncomeTaxAccrualCurrent
0
CY2022Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
139167
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
546464
CY2022Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
7970943
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
7671275
CY2022Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
125000000
CY2022Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2022Q1 us-gaap Common Stock Voting Rights
CommonStockVotingRights
one vote for each share held
CY2022Q1 us-gaap Dividend Payment Restrictions Schedule Description
DividendPaymentRestrictionsScheduleDescription
No dividends on the common stock shall be declared and paid unless dividends on the Preferred Stock have been declared and paid.
CY2022Q1 us-gaap Dividends
Dividends
0
CY2022Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1324812
CY2021Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1320002
CY2022Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1324812
CY2021Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1320002
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
10776758
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
4.97
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y25D
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
2389890
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
2426750
CY2022Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
2.73
CY2022Q1 ovid Share Based Compensation By Share Based Payment Award Options Granted Contractual Life
ShareBasedCompensationByShareBasedPaymentAwardOptionsGrantedContractualLife
P9Y9M21D
CY2022Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
13750
CY2022Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
1.91
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
434101
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
3.49
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
12755657
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
4.60
CY2022Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y9M29D
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
3079018
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
6625690
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
5.83
CY2022Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
P4Y11M4D
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
1515885
CY2022Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
12700000
CY2022Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y9M25D
CY2022Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
50000
CY2021Q4 ovid License Agreement Milestone Payments
LicenseAgreementMilestonePayments
203000000.0
CY2022Q1 us-gaap Related Party Transaction Selling General And Administrative Expenses From Transactions With Related Party
RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty
750000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-16108056
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
176007307
CY2022Q1 us-gaap Undistributed Earnings Loss Allocated To Participating Securities Basic
UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic
0
CY2021Q1 us-gaap Undistributed Earnings Loss Allocated To Participating Securities Basic
UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic
7439355
CY2022Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-16108056
CY2021Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
168567952
CY2022Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-16108056
CY2021Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
168567952
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
70345828
CY2021Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
66088592
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
70345828
CY2021Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
66578377
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.23
CY2021Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
2.55
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.23
CY2021Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
2.53

Files In Submission

Name View Source Status
0000950170-22-008739-index-headers.html Edgar Link pending
0000950170-22-008739-index.html Edgar Link pending
0000950170-22-008739.txt Edgar Link pending
0000950170-22-008739-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
img42364362_0.gif Edgar Link pending
MetaLinks.json Edgar Link pending
ovid-20220331.htm Edgar Link pending
ovid-20220331.xsd Edgar Link pending
ovid-20220331_cal.xml Edgar Link unprocessable
ovid-20220331_def.xml Edgar Link unprocessable
ovid-20220331_htm.xml Edgar Link completed
ovid-20220331_lab.xml Edgar Link unprocessable
ovid-20220331_pre.xml Edgar Link unprocessable
ovid-ex10_1.htm Edgar Link pending
ovid-ex10_1.pdf Edgar Link pending
ovid-ex31_1.htm Edgar Link pending
ovid-ex31_2.htm Edgar Link pending
ovid-ex32_1.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending